*we are a cro and lab instrumentation provider* basi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. we provide world-class research to the global pharmaceutical industry. our services include preclinical toxicology, early in vivo pk, bioanalysis and a full range of pharmaceutical analysis services. basi also manufactures innovative scientific instruments including the culex® automated in vivo sampling system which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. we are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on time.
Company profile
Ticker
NOTV
Exchange
Website
CEO
Jacqueline Lemke
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb ...
Former names
BIOANALYTICAL SYSTEMS INC
SEC CIK
Corporate docs
Subsidiaries
Inotiv Research • BAS Evansville, Inc. • Seventh Wave Laboratories, LLC • BASi Gaithersburg, LLC • Bronco Research • Histion, LLC • Inotiv Boulder, LLC • Integrated Laboratory Systems, LLC • Inotiv Nashville, LLC • Envigo Global Services, Inc. ...
IRS number
351345024
NOTV stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
19 Mar 24
10-Q
2024 Q1
Quarterly report
7 Feb 24
8-K
Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update
7 Feb 24
ARS
2023 FY
Annual report to shareholders
25 Jan 24
DEFA14A
Additional proxy soliciting materials
25 Jan 24
DEF 14A
Definitive proxy
25 Jan 24
10-K
2023 FY
Annual report
11 Dec 23
8-K
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update
11 Dec 23
8-K
Inotiv, Inc. Announces Changes to its Board Composition
19 Oct 23
10-Q
2023 Q3
Quarterly report
11 Aug 23
Transcripts
NOTV
Earnings call transcript
2024 Q1
7 Feb 24
NOTV
Earnings call transcript
2023 Q4
11 Dec 23
NOTV
Earnings call transcript
2023 Q3
10 Aug 23
NOTV
Earnings call transcript
2023 Q2
11 May 23
NOTV
Earnings call transcript
2023 Q1
13 Feb 23
NOTV
Earnings call transcript
2022 Q4
10 Jan 23
NOTV
Earnings call transcript
2022 Q3
11 Aug 22
NOTV
Earnings call transcript
2022 Q2
13 May 22
NOTV
Earnings call transcript
2022 Q1
11 Feb 22
NOTV
Earnings call transcript
2021 Q4
17 Dec 21
Latest ownership filings
3
Michael J Harrington
21 Mar 24
4
Robert Jr. Leasure
25 Jan 24
3/A
Robert Jr. Leasure
25 Jan 24
4
Andrea Castetter
16 Jan 24
4
Fernanda Beraldi
10 Jan 24
4
John E Sagartz
15 Dec 23
4
Jeffrey Brennan Freeman
15 Dec 23
4
Jeffrey Arthur Krupp
15 Dec 23
4
Beth Taylor
15 Dec 23
4
Michael Garrett
15 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
5.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 25.58 mm |
Total shares | 1.38 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Jermyn Street Associates | 1.38 mm | $25.58 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jan 24 | Andrea Castetter | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.165 | 10,000 | 41.65 k | 10,000 |
15 Dec 23 | Beth Taylor | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.0895 | 6,250 | 19.31 k | 6,250 |
15 Dec 23 | Jeffrey Arthur Krupp | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.0895 | 3,750 | 11.59 k | 3,750 |
15 Dec 23 | Sagartz John E | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.0895 | 6,250 | 19.31 k | 6,250 |
News
CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday
9 Feb 24
Jefferies Upgrades Inotiv to Buy, Raises Price Target to $11.5
9 Feb 24
Inotiv: Q1 Earnings Insights
7 Feb 24
Inotiv Q1 2024 GAAP EPS $(0.60) Beats $(0.85) Estimate, Sales $135.50M Beat $132.86M Estimate
7 Feb 24
Earnings Scheduled For February 7, 2024
7 Feb 24